Basit öğe kaydını göster

NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES

dc.contributor.authorNalcaci, Meliha
dc.contributor.authorBayrak, Ayseguel
dc.contributor.authorUcur, Ali
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorAkpinar, Timur
dc.contributor.authorCefle, Kivanc
dc.contributor.authorPalanduz, Suekrue
dc.contributor.authorElcioglu, Oemer Celal
dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorOeztuerk, Suekrue
dc.contributor.authorAktan, Melih
dc.contributor.authorCosan, Fulya
dc.date.accessioned2021-03-03T13:58:59Z
dc.date.available2021-03-03T13:58:59Z
dc.date.issued2010
dc.identifier.citationYavuz A. S. , Elcioglu O. C. , Akpinar T., Cosan F., Ucur A., Bayrak A., Cefle K., Oeztuerk S., Palanduz S., Yenerel M. N. , et al., "NILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES", NOBEL MEDICUS, cilt.6, sa.2, ss.57-62, 2010
dc.identifier.issn1305-2381
dc.identifier.othervv_1032021
dc.identifier.otherav_371fab03-737b-483b-89ce-c4c149cd4b85
dc.identifier.urihttp://hdl.handle.net/20.500.12627/41194
dc.description.abstractObjective: Clonal cytogenetic aberrations other than Philadelphia chromosome can develop during the course of chronic myeloid leukemia naturally or under the pressure of treatment strategies like interferon, imatinib and dasatinib. Some of them are associated with resistance to treatment and progression to advanced phases of chronic myeloid leukemia. Nilotinib is a second generation thyrosine kinase inhibitor, but its efficacy in chronic myeloid leukemia patients with additional chromosomal changes has not been delineated yet. In this study we evaluated the efficacy of nilotinib in imatinib-resistant or -intolerant t(9;22) positive chronic myeloid leukemia patients with and without additional chromosomal changes
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectHealth Sciences
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleNILOTINIB EFFICACY IN 21 IMATINIB-RESISTANT OR-INTOLERANT T (9;22) POSITIVE CHRONIC MYELOID LEUKEMIA PATIENTS WITH AND WITHOUT ADDITIONAL CHROMOSOMAL CHANGES
dc.typeMakale
dc.relation.journalNOBEL MEDICUS
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume6
dc.identifier.issue2
dc.identifier.startpage57
dc.identifier.endpage62
dc.contributor.firstauthorID12870


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster